Efficacy and safety of proxalutamide (GT0918) in severe or critically ill patients with COVID-19: study protocol for a prospective, open-label, single-arm, single-center exploratory trial.
BMC pharmacology & toxicology（2023）
Abstract
This study was registered on 18 June 2022 at the Chinese Clinical Trial Registry (ChiCTR2200061250).
MoreTranslated text
Key words
COVID-19, Critical ill COVID-19, Proxalutamide, Severe COVID-19
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined